Effect of triptolide on the expression of Polo-like kinase -1 in CT26 colon cancer and its antitumor activity

LU Zhi-Hao; LI Xue-Ming; JIANG Yan-Ling; ZHAO Xu; FENG Jing; LI Jian

doi:10.16098/j.issn.0529-1356.2025.01.001

PDF(5021 KB)

Acta Anatomica Sinica ›› 2025, Vol. 56 ›› Issue (1) : 4-10. DOI: 10.16098/j.issn.0529-1356.2025.01.001

Effect of triptolide on the expression of Polo-like kinase -1 in CT26 colon cancer and its antitumor activity

LU Zhi-hao LI Xue-ming JIANG Yan-ling ZHAO Xu FENG Jing LI Jian^*

Author information +

History +

Abstract

Objective To investigate the antitumor effects of triptolide against CT26 colon cancer and its impact on the expression of Polo-like kinase-1 (PLK-1) protein. Methods Forty clean grade BALB/c mice, each mouse was implanted with 1×10⁶ CT26 cells into the dorsal side of the right forelimb to establish a tumor-bearing mouse model. Experimental animals were randomly divided into four groups, the tumor model group (saline control), the positive drug group ［oxaliplatin, 5mg/(kg·d)］, the low-dose triptolide group ［50μg/(kg·/d)］, and the high-dose triptolide group ［100μg/(kg·d)］. The drugs were administered through intraperitoneal injection (10 times in total, once every other day). The in vitro effects of the drugs on the proliferation, migration, invasion, and mitosis of CT26 cells were also assessed. Results Triptolide significantly inhibited the proliferation, migration, and invasion of CT26 colon cancer cells, and disrupted the separation of centrosomes and the correct arrangement of chromosomes during the prophase of mitosis in tumor cells. The binding energy of triptolide and PLK-1 protein was -7.1 kcal/mol, and it could down-regulate the expression of PLK-1 in CT26 cells. Conclusion Triptolide exerts its antitumor effects against CT26 colon cancer by downregulating the expression of PLK-1.

Key words

Triptolide / CT26 cell line / Tumor-bearing model / Polo-like kinase-1 / Immunohistochemistry / / Mouse

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LU Zhi-hao LI Xue-ming JIANG Yan-ling ZHAO Xu FENG Jing LI Jian. Effect of triptolide on the expression of Polo-like kinase -1 in CT26 colon cancer and its antitumor activity[J]. Acta Anatomica Sinica. 2025, 56(1): 4-10 https://doi.org/10.16098/j.issn.0529-1356.2025.01.001

References

［1］Qin FX, Tian LF, Wang ZhE, et al. Exploration of the mechanism of tripterygium wilfordii in treating colon cancer based on network pharmacology and molecular docking technology ［J］. Chinese Journal of Modern Drug Applications, 2023, 17(24):141-147. (in Chinese)

秦方序, 田丽凤, 王知恩, 等. 基于网络药理学与分子对接技术探讨雷公藤治疗结肠癌的作用机制［J］.中国现代药物应用, 2023,17(24):141-147.

［2］Zhang TJ, Han S, Zhang W, et al. Triptolide promotes apoptosis of colon cancer CT26 cells by inducing autophagy ［J］. Acta Anatomica Sinica, 2016, 47(6):774-779. (in Chinese)

张天娇, 韩森, 张玮, 等. 雷公藤甲素通过诱导细胞自噬促进结肠癌 CT26 细胞死亡［J］. 解剖学报, 2016, 47(6):774-779.

［3］Li C, Li Z, Zhang T, et al. 1H NMR-based metabolomics reveals the antitumor mechanisms of triptolide in BALB/c mice bearing CT26 tumors［J］. Front Pharmacol, 2019, 11(10):1175.

［4］Shakeel I, Basheer N, Hasan GM, et al. Polo-like kinase 1 as an emerging drug target: structure, function and therapeutic implications ［J］. J Drug Target, 2021, 29(2):168-184.

［5］Kumar S, Kim J. PLK-1 targeted inhibitors and their potential against tumorigenesis ［J］. Biomed Res Int, 2015, 2015: 705745.

［6］Cui JT, Lu AG, Wang TF, et al. Expression of Polo-like kinase 1 in colorectal cancer tissues and its role in the proliferation of colorectal cancer cells［J］. Journal of Surgery Comcepts & Practice, 2010, 15(5):536-542. (in Chinese)

崔江涛, 陆爱国, 王廷峰, 等. Polo样激酶1在结肠直肠癌组织中的表达及其在结肠直肠癌细胞增殖中的作用［J］. 外科理论与实践, 2010, 15(5):536-542.

［7］Ahn DH, Barzi A, Ridinger M, et al. Onvansertib in combination with FOLFIRI and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a phase 1b clinical study［J］. Clin Cancer Res, 2024, 30(10):2039-2047.

［8］Gaillard T. Evaluation of autodock and autodock vina on the CASF-2013 benchmark［J］. J Chem Inf Model, 2018, 58 (8):1697-1706.

［9］Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials［J］. Cell, 2007,130(5): 769-774.

［10］Zhang J, Huang Q, Zhao R, et al. A network pharmacology study on the tripteryguim wilfordii Hook for treatment of Crohn’s disease［J］. BMC Complement Med Ther, 2020, 20(1):95.

［11］Feng K, Li X, Bai Y,et al. Mechanisms of cancer cell death induction by triptolide: a comprehensive overview［J］. Heliyon, 2024,10(2): e24335.

［12］Zitouni S, Nabais C, Jana SC, et al. Polo-like kinases: structural variations lead to multiple functions［J］. Nat Rev Mol Cell Biol, 2014, 15(7):433-453.

［13］Raab M, Sanhaji M, Matthess Y, et al. PLK-1 has tumor-suppressive potential in APC-truncated colon cancer cells［J］. Nat Commun, 2018(1),9:1106.

［14］Wang MW, Li Z, Chen LH, et al. Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: a systematic review and meta-analysis［J］. Front Oncol, 2022,12:917366.

［15］Ali NM, Akhtar MN, Ky M, et al. 3Flavokawain derivative FLS induced G2/M arrest and apoptosis on breast cancer MCF-7 cell line［J］. Drug Des Devel Ther, 2016, 10:1897-1907.

［16］Su S, Chhabra G, Singh CK, et al. PLK-1 inhibition-based combination therapies for cancer management［J］. Transl Oncol, 2022,16:101332.